WillItSurvive
No grouping · acquisition pending · Singapore

Regenique Group Limited

A 16-year-old Singapore aesthetics clinic chain with a stalled Nasdaq IPO.

Losing its protection
Assessed 29 July 2026 · Evidence as of 29 July 2026
The structural protection is eroding.
On the recordSince 29 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: IPO finally prices, is downsized, or is withdrawn
The call

Regenique runs a profitable, mid-pack clinic chain in a crowded market, with its stock outlook hanging on whether a nine-month-stalled IPO ever prices.

Regenique runs 25 skin and wellness clinics in Singapore that have made real money for 16 years, pulling in $11 million in sales with $3 million profit. The problem is that bigger clinics like V Medical and SL Aesthetic do almost the same thing, and there is nothing special about Regenique's treatments, brand, or how it reaches customers that would stop a competitor from copying it. The company tried to go public in late 2025 but nine months later still has no price, which tells you that big investors are not excited about betting on it, and that risk alone makes the stock shaky no matter how steady the business itself runs.

Why
01
AI pressure: AI skin-analysis apps (e.g. Perfect Corp, YouCam). AI apps can scan skin and suggest treatments, but injectables and laser work still require an in-person clinic visit. Could AI do the core job? Only partly.
02
Bigger players: SBC Medical Group (Nasdaq: SBC), V Medical, SL Aesthetic. Bigger regional chains already run more locations and compete for the same clients, with no unique treatment to set Regenique apart. Could a giant copy it? Yes, easily.
03
What protects it. Sixteen years of profit, over 300,000 past patients, and steady 25% margins keep the clinics running even without any legal or technical edge.
What would change this call
Regenique's Nasdaq IPO prices, is downsized, or is withdrawn within 6 months. Shows whether institutional demand exists or the deal is failing.
V Medical or SL Aesthetic add new outlets or bio-regenerative treatment menus. Would show larger rivals closing Regenique's already-thin differentiation.
Regenique's clinic count or revenue growth rate in next annual filing. Shows whether it is expanding regionally or staying stagnant mid-pack.
Key numbers
  • $11M TTM revenue, $3M net income (2025-06-30)
  • 25% EBIT margin in FY2024 (2024-09-30)
  • IPO filed Oct 2025, unpriced as of July 2026 (2026-07-15)
Named risks
  • IPO filed October 31, 2025 still unpriced by July 15, 2026, signaling weak institutional demand. Severity: high
  • No proprietary treatment, licensing, or IP moat; bio-regenerative menu replicable by any licensed clinic. Severity: high
  • Fragmented Singapore market with larger, better-capitalized chains like V Medical and SBC Medical. Severity: medium
  • Micro-cap thin float ($9-10M raise) likely to produce volatile post-listing price swings. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
V Medical Aesthetics & Laser Cliniclosing toV Medical runs 12+ Singapore locations vs Regenique's 5 clinics as of 2026-02-04
SBC Medical Group (Nasdaq: SBC)contestingChelsea Clinic, part of Nasdaq-listed SBC Medical Group, competes in same Singapore market as of 2026-05-10
Halley Medical AestheticscontestingEstablished Singapore aesthetics chain founded 2013, longer local presence than newer clinics
Questions people ask
Is Regenique Group profitable?
Yes. Regenique Group reported net income of about $3.04M on revenue of $10.92-11M for the trailing twelve months ended June 30, 2025, with a 25.45% EBIT margin in FY2024, per its F-1 filing.
Has Regenique Group's IPO priced yet?
No. Regenique Group filed its F-1 on October 31, 2025, targeting $4.00-5.00 per unit and a $9-10M raise, but as of July 15, 2026, nearly nine months later, the exact IPO date was still unknown and shares had not priced.
Who is Regenique Group's biggest competitor?
V Medical Aesthetics & Laser Clinic, with 12+ Singapore locations versus Regenique's 5 clinics as of February 2026, is a larger local rival, while Nasdaq-listed SBC Medical Group operates The Chelsea Clinic in the same market as of May 2026.
Could AI replace Regenique Group's clinics?
No. Regenique's core revenue comes from physician-delivered injectables, laser and energy procedures requiring MOH and Singapore Medical Council licensure. AI-enabled clinic software like Consentz only assists scheduling and documentation, not the licensed clinical service itself.
Who owns Regenique Group?
Regenique Group is Cayman Islands incorporated but Singapore headquartered, led by CEO Wong Ming Kwong as of December 10, 2025. It remains a private company pending its planned Nasdaq listing under ticker RGGG, filed October 31, 2025.
What is Regenique Group's revenue?
Regenique reported trailing-twelve-month revenue of roughly $10.92-11M USD (S$13.8M) for the period ended June 30, 2025, up from S$13.44M in FY2024 and S$12.72M in FY2023, a 5.66% year-over-year increase.
Timeline
  • 2026-07-15IPO still unpriced nearly nine months after filing; exact listing date unknown
  • 2025-12-10Company profile shows 58 employees and ~$185,485 revenue per employee
  • 2025-10-31F-1 registration statement filed with SEC for Nasdaq listing as RGGG
  • 2025-10-30IPO terms set: 2,000,000 units at $4.00-5.00, targeting $9-10M raise
  • 2025-06-30TTM revenue reported at $10.92-11M USD, net income about $3.04M
  • 2024-09-30FY2024 revenue S$13.44M, EBIT margin 25.45%
  • 2023-12-31FY2023 revenue S$12.72M, EBIT margin 24.95%
  • 2009-01Regenique Group founded in Singapore
Revision history
29 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
American Airlines GroupSafe Superintelligence Inc.Wayfair
More companies losing its protection →
Sources